Rapid translation from validated molecular targets in cancer to treatments that benefit patients has been hampered by difficulties in rapidly developing effective, targeted therapeutics, as many targets are not druggable by traditional medicinal chemistry approaches. We propose here to invesfigate a new methodology to accelerate the translation of understandings of molecular events in cancer cell biology into new therapies by using RNA interference-based therapeutics (targeted nanoparticle based systems are used here) combined with multi-time point blood/serum-based miRNA profiling. This strategy will be demonstrated using a previously undruggable target, the oncogenic N-Ras mutation in melanoma. We propose to evaluate the hypothesis that the integration of targeted delivery of RNA interference-based therapeutics that allow quick translation from concept to clinic with multi-time point blood/serum monitoring of cancer-specific miRNA biomarkers can rapidly lead to mechanistically verified cancer treatments with blood/serum biomarkers that can provide minimally invasive proof of function in patients.
Specific Aims : 1. Demonstrate tumor targeting, N-Ras knock-down, and anti-tumor effects with systemically delivered nanoparticles carrying siRNA. 2. Demonstrate that minimally invasive, multi-time point blood/serum miRNA measurements correlate with multi-time point miRNA profiles in tumors after initiation of RNAi that inhibits the N-Ras gene product. 3. Demonstrate that systemically delivered nanoparticles carrying anti-N-Ras siRNA can provide antitumor effects and that the time course of the N-Ras gene inhibition can be monitored via blood/serum miRNA profiles
The approach of integrating multi-time point blood miRMA profiling to provide pharmacodynamic monitoring matched with the specific deliverable gene knockdown has applications to any gene target in any cancer type. A secondary hypothesis implied here is that the short-time-dependent response of the profiled biomarkers can provide significant new and specific information related to therapeutic efficacy.
|Thai, Minh; Graham, Nicholas A; Braas, Daniel et al. (2014) Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab 19:694-701|
|Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25:364-73|
|Zhao, Jimmy L; Ma, Chao; O'Connell, Ryan M et al. (2014) Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell 14:445-59|
|Wong, Deborah J L; Rao, Amol; Avramis, Earl et al. (2014) Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res 2:459-68|
|Robert, Lidia; Tsoi, Jennifer; Wang, Xiaoyan et al. (2014) CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20:2424-32|
|Nathanson, David A; Gini, Beatrice; Mottahedeh, Jack et al. (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-6|
|Chodon, Thinle; Comin-Anduix, Begoña; Chmielowski, Bartosz et al. (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457-65|
|Ribas, Antoni; Tumeh, Paul C (2014) The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20:4982-4|
|Gini, Beatrice; Mischel, Paul S (2014) Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discov 4:876-8|
|Akhavan, David; Pourzia, Alexandra L; Nourian, Alex A et al. (2013) De-repression of PDGFR* transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 3:534-47|
Showing the most recent 10 out of 22 publications